Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Patient beliefs and behaviors about genomic risk for type 2 diabetes: implications for prevention.

Gallagher P, King HA, Haga SB, Orlando LA, Joy SV, Trujillo GM, Scott WM, Bembe M, Creighton DL, Cho AH, Ginsburg GS, Vorderstrasse A.

J Health Commun. 2015;20(6):728-35. doi: 10.1080/10810730.2015.1018563. Epub 2015 Apr 6.

PMID:
25844569
2.

Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in primary care patients.

Li JH, Joy SV, Haga SB, Orlando LA, Kraus WE, Ginsburg GS, Voora D.

J Pers Med. 2014 Mar 27;4(2):147-62. doi: 10.3390/jpm4020147.

3.

Effect of genetic testing for risk of type 2 diabetes mellitus on health behaviors and outcomes: study rationale, development and design.

Cho AH, Killeya-Jones LA, O'Daniel JM, Kawamoto K, Gallagher P, Haga S, Lucas JE, Trujillo GM, Joy SV, Ginsburg GS.

BMC Health Serv Res. 2012 Jan 18;12:16. doi: 10.1186/1472-6963-12-16.

4.

Clinical pearls and strategies to optimize patient outcomes.

Joy SV.

Diabetes Educ. 2008 May-Jun;34 Suppl 3:54S-59S. doi: 10.1177/0145721708319233.

PMID:
18525065
5.

Clinical pearls and strategies to optimize patient outcomes.

Joy SV.

J Am Acad Nurse Pract. 2007;19(11 Suppl 1):15-20. Review. No abstract available.

PMID:
18341244
6.

Ruboxistaurin.

Taulien CA, Joy SV.

Drugs Today (Barc). 2006 Sep;42(9):577-85. Review.

PMID:
17028667
7.

Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.

Joy SV, Scates AC, Bearelly S, Dar M, Taulien CA, Goebel JA, Cooney MJ.

Ann Pharmacother. 2005 Oct;39(10):1693-9. Epub 2005 Sep 13. Review.

PMID:
16160002
8.

Incretin mimetics as emerging treatments for type 2 diabetes.

Joy SV, Rodgers PT, Scates AC.

Ann Pharmacother. 2005 Jan;39(1):110-8. Epub 2004 Nov 23. Review.

PMID:
15562141

Supplemental Content

Loading ...
Support Center